<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="en"><front><journal-meta><journal-id journal-id-type="publisher-id">mvjr</journal-id><journal-title-group><journal-title xml:lang="en">Medical Herald of the South of Russia</journal-title><trans-title-group xml:lang="ru"><trans-title>Медицинский вестник Юга России</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">2219-8075</issn><issn pub-type="epub">2618-7876</issn><publisher><publisher-name>The Rostov State Medical University</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.21886/2219-8075-2022-13-1-117-123</article-id><article-id custom-type="elpub" pub-id-type="custom">mvjr-1459</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>ALLERGOLOGY AND IMMUNOLOGY</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>АЛЛЕРГОЛОГИЯ И ИММУНОЛОГИЯ</subject></subj-group></article-categories><title-group><article-title>The role of innate immunity in the formation of various variants of the course of seasonal allergic rhinitis</article-title><trans-title-group xml:lang="ru"><trans-title>Роль врожденного иммунитета в формировании различных вариантов течения сезонного аллергического ринита</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-5716-4397</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Сизякина</surname><given-names>Л. П.</given-names></name><name name-style="western" xml:lang="en"><surname>Sizyakina</surname><given-names>L. P.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Сизякина Людмила Петровна - доктор медицинских наук, профессор, заведующий кафедрой клинической иммунологии и аллергологии.</p><p>Ростов-на-Дону</p></bio><bio xml:lang="en"><p>Lyudmila P. Sizyakina - Dr. Sci. (Med.), professor, head of the department of clinical immunology and allergology.</p><p>Rostov-on-Don</p></bio><email xlink:type="simple">msiziakina@mail.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-7735-4275</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Андреева</surname><given-names>И. И.</given-names></name><name name-style="western" xml:lang="en"><surname>Andrreeva</surname><given-names>I. I.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Андреева Ирина Ивановна - доктор медицинских наук, профессор кафедры клинической иммунологии и аллергологии.</p><p>Ростов-на-Дону</p></bio><bio xml:lang="en"><p>Irina I. Andreeva - Dr. Sci. (Med.), professor of the department of clinical immunology and allergology.</p><p>Rostov-on-Don</p></bio><email xlink:type="simple">iai3012@rambler.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-2281-4684</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Семенова</surname><given-names>Н. И.</given-names></name><name name-style="western" xml:lang="en"><surname>Semenova</surname><given-names>N. I.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Семенова Наталья Ивановна - кандидат медицинских наук, врач аллерголог-иммунолог консультативно-диагностического отделения.</p><p>Ростов-на-Дону</p></bio><bio xml:lang="en"><p>Natalya I. Semenova - Cand. Sci. (Med.), Consultative and Diagnostic Department.</p><p>Rostov-on-Don</p></bio><email xlink:type="simple">nata.semyonowa2012@yandex.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-0806-6437</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Харитонова</surname><given-names>М. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Kharitonova</surname><given-names>M. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Харитонова Мария Владимировна - кандидат медицинских наук, заведующая лабораторией клинической иммунологии и аллергологии.</p><p>Ростов-на-Дону</p></bio><bio xml:lang="en"><p>Maria V. Kharitonova - Cand. Sci. (Med.), Head of the Laboratory of Clinical Immunology and Allergology.</p><p>Rostov-on-Don</p></bio><email xlink:type="simple">mari.Kharitonova.80@mail.ru</email><xref ref-type="aff" rid="aff-2"/></contrib></contrib-group><aff xml:lang="ru" id="aff-1"><institution>Ростовский государственный медицинский университет</institution><country>Russian Federation</country></aff><aff-alternatives id="aff-2"><aff xml:lang="ru"><institution>Ростовский государственный медицинский университет</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Rostov State Medical University</institution><country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2022</year></pub-date><pub-date pub-type="epub"><day>30</day><month>03</month><year>2022</year></pub-date><volume>13</volume><issue>1</issue><fpage>117</fpage><lpage>123</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Sizyakina L.P., Andrreeva I.I., Semenova N.I., Kharitonova M.V., 2022</copyright-statement><copyright-year>2022</copyright-year><copyright-holder xml:lang="ru">Сизякина Л.П., Андреева И.И., Семенова Н.И., Харитонова М.В.</copyright-holder><copyright-holder xml:lang="en">Sizyakina L.P., Andrreeva I.I., Semenova N.I., Kharitonova M.V.</copyright-holder><license license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://www.medicalherald.ru/jour/article/view/1459">https://www.medicalherald.ru/jour/article/view/1459</self-uri><abstract><sec><title>Purpose</title><p>Purpose: to study the functional parameters of the innate immune response in various clinical courses of seasonal allergic rhinitis.</p></sec><sec><title>Materials and methods</title><p>Materials and methods: a comparative prospective study was conducted. 62 participants (patients with seasonal allergic rhinitis) were divided into subgroups with mild (34 people) and moderate (28 people). Th e parameters of the innate immune response were studied. Th e assessment was carried out during the exacerbation period, before the appointment of therapy and in remission, outside the palination season.</p></sec><sec><title>Results</title><p>Results: changes in the cells of the innate immune response in patients with seasonal allergic rhinitis are formed at the earliest stages of clinical manifestation, aff ect the functional potential of natural killer cells and the oxygen-producing activity of the neutrophilic link, and are stable outside the palination season. Increased production of proinfl ammatory and immunoregulatory mediators is a key manifestation of the progression of seasonal allergic rhinitis.</p></sec><sec><title>Conclusion</title><p>Conclusion: inhibition of the functional resources of innate immunity cells and cytokine dysregulation can play a significant role in the development of complications of seasonal allergic rhinitis caused by secondary immune defi ciency.</p></sec></abstract><trans-abstract xml:lang="ru"><sec><title>Цель</title><p>Цель: изучение динамики параметров врожденного иммунного ответа у больных с различными вариантами течения сезонного аллергического ринита.</p></sec><sec><title>Материалы и методы</title><p>Материалы и методы: в сравнительном проспективном исследовании участвовали 62 больных сезонным аллергическим ринитом, разделенных на подгруппы с легкой степенью (34 человека) и среднетяжелым вариантом течения (28 человек). Параметры врожденного иммунного ответа оценивали в двух контрольных точках: в период обострения, до назначения терапии и в ремиссию, вне сезона палинации.</p></sec><sec><title>Результаты</title><p>Результаты: изменения реагирования клеточных компонентов врожденного иммунного ответа у больных сезонным аллергическим ринитом формируются на самых ранних этапах клинической манифестации, затрагивают функциональный потенциал натуральных киллеров и кислородпродуцирующую активность нейтрофильного звена, стабильны вне сезона палинации. Ключевым проявлением прогрессии из легкого варианта в среднетяжелую форму является цитокиновый дисбаланс в виде усиления продукции провоспалительных и иммунорегуляторных медиаторов.</p></sec><sec><title>Заключение</title><p>Заключение: угнетение функциональных ресурсов клеток врожденного иммунитета и цитокиновая дисрегуляция могут играть значимую роль при развитии осложнений сезонного аллергического ринита, обусловленных вторичной иммунной недостаточностью.</p></sec></trans-abstract><kwd-group xml:lang="ru"><kwd>сезонный аллергический ринит</kwd><kwd>врожденный иммунный ответ</kwd><kwd>цитокины</kwd></kwd-group><kwd-group xml:lang="en"><kwd>seasonal allergic rhinitis</kwd><kwd>innate immunity</kwd><kwd>cytokines Financing</kwd></kwd-group><funding-group><funding-statement xml:lang="ru">Статья публикуется без спонсорской поддержки</funding-statement><funding-statement xml:lang="en">The article is published without sponsorship</funding-statement></funding-group></article-meta></front><body><sec><title>Introduction</title><p>Seasonal allergic rhinitis (SAR) is rightfully attributed to the leaders of allergic pathology from the position of prevalence [<xref ref-type="bibr" rid="cit1">1</xref>][<xref ref-type="bibr" rid="cit2">2</xref>]. In order to control SAR, technologies for topical identification of causally significant allergens are being developed very intensively; treatment and prevention approaches are being improved. Success in solving these problems can be based only on the knowledge of the mechanisms of disease immunopathogenesis [3–5]. The involvement of specific immune reactions according to the Th2 variant in the formation of atopy is beyond doubt [<xref ref-type="bibr" rid="cit6">6</xref>][<xref ref-type="bibr" rid="cit7">7</xref>]. Meanwhile, more and more data are accumulated on the involvement of antigen-independent immune processes in the immunopathogenesis of allergic diseases, including SAR [<xref ref-type="bibr" rid="cit8">8</xref>][<xref ref-type="bibr" rid="cit9">9</xref>]. Currently, no one doubts the postulate about the importance of innate immunity in the implementation of specific immune processes, as well as about the effects of adaptive reactions on the potential of the innate immune response. It is known that the innate response to allergen proteases, including pollen, can induce cytokines of epithelial origin IL-33, IL-25, and thymic stromal lymphopoietin, which lead to activation of lymphocytes of the innate immune system ILC 2 in order to release cytokines of type 2 in an antigen-independent manner [<xref ref-type="bibr" rid="cit10">10</xref>]. The conditions associated with the activation of mast cells and ILC 2 create the orientation of differentiation of macrophage cells in the M2 phenotype and ensure their participation in the maintenance of inflammation and the clinical manifestation of SAR [<xref ref-type="bibr" rid="cit11">11</xref>][<xref ref-type="bibr" rid="cit12">12</xref>]. The pathobiological role of the listed factors of the innate immune response in maintaining local allergic inflammation is being actively studied [<xref ref-type="bibr" rid="cit13">13</xref>]. Meanwhile, data on changes in systemic immunogenesis formed in response to the progression of local type 2 inflammation have been little studied and are quite controversial. At the same time, the dynamics of these processes may be significant in the choice of a clinical manifestation scenario, the prognosis of the SAR course.</p><p>The aim of this particular study was to study the dynamics of the parameters of the innate immune response in patients with various SAR course variants.</p></sec><sec><title>Materials and methods</title><p>A comparative prospective empirical study to assess the immune system indicators depending on the severity of the clinical SAR course was conducted at the Department of Clinical Immunology and Allergology on the basis of the allergologist-immunologist office of the consultative diagnostic department and the Laboratory of Clinical Immunology and Allergology of RostSMU. The study involved patients with SAR, divided into subgroups with mild (34 people) and moderate (28 people) variants of the course, both men and women aged 18 to 50 years.</p><p>The study consisted of two control points. The initial examination happened during the period of pronounced clinical manifestation, during the dusting season of a causally significant allergen, while contacting an advisory polyclinic, before the appointment of therapy. The second examination was during remission lasting at least two months outside the pollination season. The study took place during the period from July 2017 to March 2019.</p><p>The inclusion criteria were age, a confirmed diagnosis of mild or moderate SAR with at least two years of disease experience, and proven sensitization to pollen allergens, without the use of the ACIT method to control the disease. Pregnant, lactating, patients with comorbid somatic pathology in the stage of subcompensation or decompensation, with a newly diagnosed diagnosis of SAR, in the presence of signs of acute infectious pathology, were excluded from the study. All the patients signed informed consent to participate in the study in accordance with the protocol approved by the Local Independent Ethics Committee of the Federal State Medical University of RostSMU (Protocol No. 18/13 dated December 13, 2013). The diagnosis of SAR was made in accordance with Federal Clinical Guidelines for the Diagnosis and Treatment of Allergic rhinitis [<xref ref-type="bibr" rid="cit14">14</xref>].</p><p>The anamnestic data, the results of clinical examination and the severity of the main SAR symptoms during the period of exacerbation were evaluated: nasal congestion, rhinorrhea, itching in the nose, and sneezing. In order to objectify the results of the clinical examination, the total nasal symptom score (TNSS) scale was used [<xref ref-type="bibr" rid="cit15">15</xref>], as well as a standardized questionnaire on the quality of life of allergic rhinitis patients – Rhinitis Quality of Life Questionnaire (RQLQ) [<xref ref-type="bibr" rid="cit16">16</xref>].</p><p>The methods of investigation during the dusting season and the clinical manifestation of SAR consisted in conducting and evaluating microscopy data of nasal mucus. Microscopy was performed after smear staining using the Romanovsky–Giemza method to characterize the cellular composition of mucus. Outside of the flowering season, in the absence of intercurrent acute respiratory viral infections, patients underwent scarification skin tests with water-salt extracts of pollen allergens. The degree of sensitization was assessed by the severity of the local reaction on the palmar surface of the forearm 20 minutes after sampling. Accounting was carried out in the following points: 0 – the size and appearance of the local reaction are similar to the reaction in the control; 1 – a blister of 2–3 mm in size at the scarification site, visible only when the skin is stretched; 2 – a blister of no more than 5 mm, surrounded by hyperemia at the scarification site, clearly visible when the skin is stretched; 3 – a blister of 6–10 mm, surrounded by hyperemia; 4 – a blister of more than 10 mm.</p><p>When characterizing the parameters of innate immunity in the peripheral circulation, the number of natural killers (NKs) (CD3-CD16+), the number of their cytolytically active forms containing intracellular granzyme B granules (CD3-CD16+GrB+), and the number of monocytes carrying TLR2 (CD14+CD282+) and TLR4 (CD14+CD284+) receptors for pattern recognition were estimated. For this purpose, flow cytofluorometry was conducted using Cytomics FC 500 (Beckman Coulter, USA) and sets of monoclonal antibodies with two and three-color labels corresponding to the tasks (manufactured by Beckman Coulter, USA). The formation of reactive oxygen species (ROS) by neutrophils was recorded using the NBT test, while evaluating spontaneous values (NBT sv), the results obtained under conditions of additional stimulation of neutrophils in vitro (NBT st) and calculating the coefficient of stimulation Kst. (NBT st./NBT sv.). Quantitative assessment of the content of cytokines in blood serum TNF-α, IL-6, IL-4, and IFN-γ was carried out by enzyme immunoassay on Vector-Best test systems (RF).</p><p>As a control group, the corresponding indicators of the immune system of practically healthy blood donors with no indication of a history of somatic pathology, including allergies, were evaluated only once.</p><p>Statistical data processing was carried out using the software package Statistica for Windows 6.1 (StatSoft, USA). In the first stage, descriptive statistics were carried out using exploratory analysis; the nature of the distribution of quantitative data was evaluated according to the Shapiro-Wilk criterion (since the sample sizes were &gt;50 people). In cases where the sample obeyed the normal distribution law, the averaged data were presented in the form of mathematical expectation (M) and standard deviation (SD) M±SD. If the sample did not obey the normal probability law, then the median (Me) and the 25th and 75th percentile (Q1:Q3) were used in the description, presenting the data in the form of Me [Q1;Q3]. After that, a pairwise comparative analysis of independent data was performed, comparing alternately a group with a mild severity of the current/control group, a group with a moderate severity of the current/control group, a group with a mild degree/a group with a moderate severity. If the distribution of data (for each factor) was subject to the normal probability law in both groups being compared, a parametric Student's t-test was used to check the significance level of the differences. If, however, in at least one of the two groups compared, the factor data were not distributed according to the normal probability law, and also when both samples did not obey the normal probability law, the nonparametric Mann-Whitney criterion was applied. The differences between the groups were considered statistically significant at p&lt;0.05; in the opposite case, the differences were considered statistically insignificant (p&gt;0.05).</p></sec><sec><title>Results</title><p>The data on the clinical characteristics of patients allowed distinguishing two groups of subjects: group I (34 people) – with a mild degree of severity of the course of SAR, and group II – (28 people) with a medium-heavy version of the course. The patients were comparable in age (30±5.5 and 33±5.7 years, respectively), gender (men – 41 and 46; women – 59 and 54), the length of illness (7.7±2.7 and 10.8±3.5 years), the duration of the acute SAR period (2.9±1.7 and 3.6±1.9 months), and the presence of hereditary predisposition according to the results of allergic anamnesis (47% and 46%).</p><p>Rhinorrhea, burning and tickling sensations in the nose, difficulty in nasal breathing, itching, and paroxysmal sneezing were noted in all patients with a mild variant of the clinical SAR course. The data from the analysis of the tables of the main symptoms showed that nasal congestion was the most significant, and the score reflecting this sign was less pronounced with immediate assessment (i-TNSS 1.59±0.5 in the evening, 1.59±0.5 in the morning) than with retrospective assessment (r-TNSS — 1.97±0.30 in the evening and 1.94±0.34 in the morning). The sum of the i-TNSS scores (1.29±0.14) was also slightly lower than the total score of the r-TNSS scale, which was 1.44±0.21. The average value of the total score of the RQLQ quality of life assessment questionnaire in a subgroup of patients was 80.6±8.86, which is almost two times less than the maximum possible when using this test. It should also be noted that the highest average value is the indicator reflecting the inconvenience caused by the general symptoms of the disease (17.2±3.45), and the lowest (7.1±1.82) – by sleep disorders.</p><p>The analysis of the indicators of the innate link of the immune response demonstrates an increase in the production of ROS by neutrophil granulocytes. This fact is confirmed by an increased indicator of the spontaneous NBT test in comparison with the control parameters (97.0 [ 90.0; 107.0] CU, in the control 90 [ 88; 91], p=0.012). At the same time, with additional stimulation of neutrophils in vitro, oxygen-producing activity was lower (150.0 [ 142.0; 171.0] cu) than in healthy (203 [ 192;217], p=0.011). This fact is reflected in the reduced value of the NBT-stimulation coefficient (1.60 [ 1.50; 1.70], in the control 2.0 [ 1.8; 2.1], p=0.011). The nature of changes in the parameters of the lymphoid component of innate immune protection demonstrated the preservation of the quantitative parameters of NKs: the relative number of circulating CD16+ lymphocytes did not differ from the data of the control group (respectively 10.50 [ 7.00; 13.00] and 12 [ 10.00; 13.00], p=0.86). At the same time, one should note the inhibition of the functional properties of these cells, which is more noticeably confirmed by a decrease in the absolute amount of NKs containing lytic granules of granzyme B (0.084 [ 0.058;0.124] 109/l, in the control 0.14 [ 0.11; 0.16], p=0.011). The data reflecting the ability of peripheral blood monocytes to recognize pathogen-associated patterns did not differ from the control values of the number of CD14+CD282+ (59.5[ 49.0; 70.0] and 64 [ 55.0; 70.0], p=0.15) and CD14+CD284+ cells (20.0 [ 11.0; 30.0]% and 20 [ 15.0; 23.0], p=0.078). It should also be noted that there are no statistically significant differences in serum levels of immune response mediators.</p><p>As for the patients of the second subgroup, which consisted of people with a moderate variant of the SAR course, the indicators of objectification of TNSS symptoms varied around the maximum level (3 points). The “nasal congestion” criterion was most pronounced, which was noted both with retrospective (r-TNSS 2.96±0.19 in the evening and 2.93± 0.26 in the morning) and immediate assessment (i-TNSS 2.96±0.19 in the evening and 3.00± 0.00 in the morning). The factor of the total RQLQ score also looks very clear: its average value in the subgroup was only 15% less than the maximum possible, amounting to 143.2±5.28. At the same time, most of the points were determined by the “general symptoms” factor (34.8±3.87).</p><p>While characterizing the parameters of cellular factors of the innate defense system, there were no changes in the receptor expression of peripheral blood monocytes in relation to practically healthy ones. So, the relative number of CD14+CD282+ (60.50 [ 50.50; 68.00]%) and CD14+CD284+ mononuclears (20.00  [ 12.05; 29.50]%) did not differ from the control (64 [ 55.0; 70.0]% at p=0.68 and 20 [ 15.0; 23.0]% at p=0.87, respectively); the number of circulating NKs and the spontaneous metabolic activity of neutrophils were also within the values of practically healthy donors. At the same time, the functional potential of these cell lines was reduced. This fact documents a decrease in the value of the stimulated NBT test (136.0 [ 127.0; 163.5] c.u., in the control 203 [ 192;217] c.u., p=0.011), as well as the coefficient of stimulation of NBT (1.50 [ 1.40;1.60], in the control 2.0 [ 1.8;2.1], p =0.019). In addition, there was a decrease in the relative number of circulating cytolytically active NKs (CD16+Gr+, % 6.00 [ 4.00; 10.00], in the control 10 [ 8; 12], p=0.02). The analysis of the cytokine spectrum of blood serum indicates shifts in this immune response system: the content of proinflammatory mediators IL-6 was significantly increased: 7.3 [ 5.1;9.4] pg/ml, in the control 2.0[ 1.2;2.4], p=0.01 and TNF-α [ 2.3 [ 1.7;3.4] pg/ml, in the control 1.6[ 1.4;1.9], p=0.01. In addition, the values of immunoregulatory oppositional cytokines IFN-γ (8.9 [ 7.0;11.2] pg/ml, in the control 6.2[ 4.9;6.8], p=0.02) and IL were increased (3.2 [ 1.9;4.3], pg/ml, in the control 2.1[ 1.0;2.4], p=0.03).</p><p>While solving the problem of searching for distinctive signs in the reaction of systemic indicators of innate immunity, depending on the variant of the course of SAR, a comparison of data characterizing a mild degree of clinical course with a moderate variant of SAR in the stage of exacerbation of allergic inflammation was carried out. A comparison of the clinical picture, based on a comparison of the scores of evaluation scales, revealed statistically significant differences in the i-TNSS criteria reflecting each of the symptoms, their average values of both morning and evening indicators, as well as the overall score: in the mild SAR case, its value was 1.29±0.14, and in the moderate case – 2.70±0.16, p&lt;0.001. Similar dynamics can be traced when comparing the results of r-TNSS in values that characterize not only each of the symptoms, but also the total score of the average values of morning and evening indicators (1.44±0.21 for the mild variant, 2.65±0.27 for the moderate, p&lt;0.001, respectively). The comparison of the quality of life assessment data also looks convincing. Thus, with a mild clinical course, the values of the RQLQ criteria ranged from 30 to 60% of the total score, and with a moderate variant, the spread of values was no more than 10% with a total increase to 85–90%.</p><p>A comparison of the indicators of the cellular link of innate immunity in patients with mild and moderate forms of SAR revealed no differences in the production of ROS by neutrophil phagocytes, in the expression of Toll-like receptors 2 and 4 by peripheral blood monocytes, in the number of circulating NKs and cytolytically active granzyme-positive CD16+ lymphocytes. At the same time, in patients with a moderate form, in comparison with patients with a mild variant of the clinical course, an increase in the serum content of all cytokines analyzed in the work is recorded. To a greater extent, this fact distinguishes the pro-inflammatory mediator IL-6 (Table 1).</p><table-wrap id="table-1"><caption><p>Таблица / Table 1</p><p>Показатели врожденного иммунного ответа при различных вариантах клинического течения сезонного аллергического ринита в период обострения</p><p>Indices of the innate immune response in different variants of the clinical course of seasonal allergic rhinitis during an exacerbation</p></caption><table><tbody><tr><td>Параметры
Indicators</td><td>Легкое течение
Mild form (n=34)</td><td>Среднетяжелое течение
Moderate form (n=28)</td><td>р</td></tr><tr><td>НК (%)
NK (%)</td><td>10.50[ 7.00; 13.00]</td><td>11.20[ 8.00; 14.00]</td><td>0,66</td></tr><tr><td>НК (абс)
NK (abs)</td><td>0.173[ 0.106; 0.258]</td><td>0.179[ 0.121; 0.232]</td><td>0,54</td></tr><tr><td>НК цитолитические (%)
NK cytolytic (%)</td><td>5.0[ 3.0; 8.0]</td><td>6.00 [ 4,00; 10,00]</td><td>0,76</td></tr><tr><td>НК цитолитические (абс)
NK cytolytic (abs)</td><td>0.084[ 0.058; 0.124]</td><td>0,106 [ 0,081; 0,202]</td><td>0,34</td></tr><tr><td>Моноциты TLR2+ (%)
Monocytes TLR2+ (%)</td><td>59.5[ 49.0; 70.0]</td><td>60,50 [ 50,50; 68,00]</td><td>0,59</td></tr><tr><td>Моноциты TL2+ (абс)
Monocytes TLR2+(abs)</td><td>0.195[ 0.121; 0.265]</td><td>0,177 [ 0,091; 0,253]</td><td>0,24</td></tr><tr><td>Моноциты TL4+ (%)
Monocytes TL4+ (%)</td><td>20.0[ 11.0; 30.0]</td><td>20,00 [ 12,05; 29,50]</td><td>0,25</td></tr><tr><td>Моноциты TL4+ (абс)
Monocytes TL4+(abs)</td><td>0.056[ 0.030; 0.110]</td><td>0,051 [ 0,029; 0,098]</td><td>0,34</td></tr><tr><td>Продукция нейтрофилами АФК (у.е.)
Production of reactive oxygen species by neutrophils (c.u.)</td><td>Cпонтанная
Spontaneous</td><td>97.0[ 90.0; 107.0]</td><td>93,00 [ 85,00; 104,50]</td><td>0,51</td></tr><tr><td>Стимулиров
Stimulated</td><td>150.0[ 142.0; 171.0]</td><td>136,0 [ 127,0; 163,5]</td><td>0,41</td></tr><tr><td>К ст.
К st.</td><td>1.60[ 1.50; 1.70]</td><td>1,50 [ 1,40 ;1,60 ]</td><td>0,19</td></tr><tr><td>IL-4 (пг/мл)
IL-4 (pg/ml)</td><td>1. 7 [ 0.5;2.1]</td><td>*3.8 [ 1.9;4.7]</td><td>0.01</td></tr><tr><td>IL-6 (пг/мл)
IL-6 (pg/ml)</td><td>2.3 [ 1.5;3.1]</td><td>*7,3[ 5.1;9.4]</td><td>0.001</td></tr><tr><td>IFN-γ (пг/мл)
IFN-γ (pg/ml)</td><td>5.2[ 3.2;6,1]</td><td>*8.9 [ 7.0;11.2]</td><td>0.03</td></tr><tr><td>TNF-α (пг/мл)
TNF-α (pg/ml)</td><td>1.1 [ 0.5;1,7]</td><td>*2,3 [ 1.7;3,4]</td><td>0.02</td></tr></tbody></table></table-wrap><p>It is also known that there is a persistent inflammation of the nasal mucosa in patients with SAR even in the absence of a causally significant allergen [<xref ref-type="bibr" rid="cit17">17</xref>][<xref ref-type="bibr" rid="cit18">18</xref>]. This circumstance determined the interest in analyzing the indicators of the innate immune response in the same patients, but in remission. The authors of this study found that with a mild variant of the SAR course, in comparison with the control parameters of practically healthy donors, the production of ROS by neutrophils in the in vitro additional stimulation test was reduced (NBT st., c.u. 141.5[ 125.0; 156.0] c.u., in the control 203[ 192;217], p=0.012). At the same time, the indicators of the spontaneous NBT test do not differ between the groups (respectively 93.0[ 80.0; 98.0] c.u. and 90 [ 88; 91], c.u., p =0.89). The attention is also drawn to the value of the parameter reflecting the functional properties of the lymphoid subpopulation of innate immunity. The number of CD16+Gr+ cells in the circulation was reduced (5.0[ 4.0; 8.0%, in the control 10 [ 8; 12], p=0.01). At the same time, there were no statistically significant differences in the expression of TLR 2 and TLR 4 by monocyte cells, and there were no differences in the serum content of immune response mediators. During the period of remission of the moderate SAR variant, in comparison with the control group, the parameters of the stimulated NBT test were reduced (136.0 [ 127.0; 163.5] c.u., p=0.02), a decrease in the proportion of functionally active CD16+Gr+ lymphocytes was recorded (7.30 [ 3.50; 9.50]%, p=0.014) while preservation in comparison with the values of control of quantitative indicators of NKs, expression by cells of the TLR2 and TLR4 monocyte series, the content of cytokines IL-4; IL-6; IFN-γ; TNF-α in the blood serum. A comparison of the data reflecting the functional potencies of the cellular components of innate immunity in the conditions of remission of moderate and mild SAR revealed no statistically significant differences in the metabolic activity of neutrophils, monocytic expression of TLR 2 and TLR4, lytic properties of NKs, and cytokine profile of blood serum.</p></sec><sec><title>Discussion</title><p>The stage of exacerbation of mild SAR manifests an increase in the metabolic activity of the neutrophil link and weakening of patients’ adaptive resources in relation to the parameters of practically healthy people. A decrease in functional potencies also distinguishes the population of NKs. In patients with moderate-severity SAR in the stage of exacerbation, in comparison with the control figures, changes in the functioning of the immune system are manifested by a decrease in the reserves of metabolic activity of neutrophil phagocytes and lytic potencies of NKs. A very significant factor is the systemic activation of cytokine production of both pro-inflammatory and regulatory orientation, while the content of IL-6 in the peripheral serum is increased to a greater extent, and the fact of increased synthesis of mediators of both Th1 and Th2 profiles is also very interesting. It should be noted that it is this circumstance – the production of immune response mediators – that distinguishes the systemic response of the innate immune response depending on the severity of the clinical SAR course. A very important result of the observation is the detection of changes in the functioning of innate immune response cells in patients with SAR compared with control criteria in the absence of causally significant allergens. Changes in mild SAR patients during clinical remission are determined by a decrease in the effector potencies of neutrophils and NKs. In the absence of pollination and clinical manifestations of SAR of the moderate course variant, the suppression of adaptive reserves of oxygen-dependent metabolism of neutrophil granulocytes and the cytolytic potential of NK cells continues to be recorded, and there are no fundamental differences from the data of the same period in patients with a mild course variant. If the peculiarities of the functioning of the immune system in patients with acute SAR are justified by the current allergic inflammation, then the quantitative and functional indicators of innate immunity that differ from the control data in the stage of clinical remission are objective evidence of a violation of the systemic immune response even in the absence of a causally significant allergen and at the earliest stages of the disease.</p></sec><sec><title>Conclusion</title><p>The totality of the presented data allows stating that changes in the response of cellular components of the innate immune response in SAR patients are formed in the earliest stages of clinical manifestation, are stable outside the season of pollination and severity, and the key manifestation of progression is cytokine imbalance. Inhibition of the adaptive potential of neutrophil phagocytes and the lytic activity of NKs can play a significant role in the development of complications of SAR caused by secondary immune insufficiency.</p></sec></body><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Ильина Н.И., Лусс Л.В., Курбачева О.М., Назарова Е.В., Павлова К.С. Влияние климатических факторов на спектр и структуру аллергических заболеваний на примере Московского региона. Российский аллергологический журнал. 2014;(2):25-31. eLIBRARY ID: 21503934</mixed-citation><mixed-citation xml:lang="en">Ilyina N.I., Luss L.V., Kurbacheva O.M., Nazarova E.V., Pavlova K.S. Th e infl uence of climatic factors on the spectrum and structure of allergic diseases in the case of the Moscow region. Russian journal of allergy. 2014;(2):25-31. (In Russ.) eLIBRARY ID: 21503934</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Хаитов М.Р., Намазова-Баранова Л.С., Ильина Н.И., Курбачёва О.М., Bachert C, и др. ARIA 2019: алгоритмы оказания помощи при аллергическом рините в России. Российский Аллергологический Журнал. 2020;17(1):7-22. DOI: 10.36691/RAJ.2020.17.1.001</mixed-citation><mixed-citation xml:lang="en">Khaitov M.R., Namazova-Baranova L.S., Ilyina N.I., Kurbacheva O.M., Bachert C. et al. 2019 ARIA: care pathways for allergic rhinitis in Russia. Russian Journal of Allergy. 2020;17(1):7-22. (In Russ.) DOI: 10.36691/RAJ.2020.17.1.001</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Гущин И.С. IgE-опосредованная гиперчувствительность как ответ на нарушение барьерной функции тканей. Иммунология. 2015;36(1):45-52. eLIBRARY ID: 23183300</mixed-citation><mixed-citation xml:lang="en">Gushchin I.S. IgE-mediated hypersensitivity as a response to barrier tissue disfunction. Immunologiya. 2015;36(1):45-52. (In Russ.) eLIBRARY ID: 23183300</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Tohidinik HR, Mallah N, Takkouche B. History of allergic rhinitis and risk of asthma; a systematic review and metaanalysis. World Allergy Organ J. 2019;12(10):100069. DOI: 10.1016/j.waojou.2019.100069</mixed-citation><mixed-citation xml:lang="en">Tohidinik HR, Mallah N, Takkouche B. History of allergic rhinitis and risk of asthma; a systematic review and metaanalysis. World Allergy Organ J. 2019;12(10):100069. DOI: 10.1016/j.waojou.2019.100069</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Солдатов А.А., Авдеева Ж.И., Медуницын Н.В. Механизмы аллергической реакции немедленного типа, препараты и методы специфической иммунотерапии. Иммунология. 2016;37(1):51-60. DOI: 10.18821/0206-4952-2016-37-1-51-60</mixed-citation><mixed-citation xml:lang="en">Soldatov A.A., Avdeeva Zh.I., Medunitsin N.V. Mechanisms of allergic reactions of immediate type, drugs and methods of immunotherapy. Immunologiya. 2016;37(1):51-60. (In Russ.) DOI: 10.18821/0206-4952-2016-37-1-51-60</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Kappen JH, Durham SR, Veen HI, Shamji MH. Applications and mechanisms of immunotherapy in allergic rhinitis and asthma. Th er Adv Respir Dis. 2017;11(1):73-86. DOI: 10.1177/1753465816669662</mixed-citation><mixed-citation xml:lang="en">Kappen JH, Durham SR, Veen HI, Shamji MH. Applications and mechanisms of immunotherapy in allergic rhinitis and asthma. Th er Adv Respir Dis. 2017;11(1):73-86. DOI: 10.1177/1753465816669662</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Zielen S, Devillier P, Heinrich J, Richter H, Wahn U. Sublingual immunotherapy provides long-term relief in allergic rhinitis and reduces the risk of asthma: A retrospective, real-world database analysis. Allergy. 2018;73(1):165-177. DOI: 10.1111/all.13213</mixed-citation><mixed-citation xml:lang="en">Zielen S, Devillier P, Heinrich J, Richter H, Wahn U. Sublingual immunotherapy provides long-term relief in allergic rhinitis and reduces the risk of asthma: A retrospective, real-world database analysis. Allergy. 2018;73(1):165-177. DOI: 10.1111/all.13213</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Сизякина Л.П., Андреева И.И., Семенова Н.И. Особенности иммунного статуса больных среднетяжелой формой сезонного аллергического ринита. Российский аллергологический журнал. 2016;(6):18-22. eLIBRARY ID: 28125275</mixed-citation><mixed-citation xml:lang="en">Sizyakina L.P., Andreeva I.I., Semenova N.I. Immune parameters in moderate seasonal allergic rhinitis. Russian Journal of Allergy. 2016;(6):18-22. (In Russ.) eLIBRARY ID: 28125275</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Лусс Л.В., Ильина Н.И., Шульженко А.Е., Назарова Е.В., Шартанова Н.В., Сидорович О.И. Основные причины и факторы формирования иммунных дисфункций у человека и современные подходы к их коррекции. Российский аллергологический журнал. 2019;16(2):82-92. eLIBRARY ID: 38595682</mixed-citation><mixed-citation xml:lang="en">Luss L.V., Ilina N.I., Shuljenko A.E., Nazarova E.K., Shartanova N.V., Sidorovich O.I. Th e main causes and factors of immune dysfunctions in humans and modern approaches to their correction. Russian Journal of Allergy. 2019;16(2):82-92. (In Russ.) eLIBRARY ID: 38595682</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Ebbo M, Crinier A, Vély F, Vivier E. Innate lymphoid cells: major players in infl ammatory diseases. Nat Rev Immunol. 2017;17(11):665-678. DOI: 10.1038/nri.2017.86</mixed-citation><mixed-citation xml:lang="en">Ebbo M, Crinier A, Vély F, Vivier E. Innate lymphoid cells: major players in infl ammatory diseases. Nat Rev Immunol. 2017;17(11):665-678. DOI: 10.1038/nri.2017.86</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Schleimer RP. Immunopathogenesis of Chronic Rhinosinusitis and Nasal Polyposis. Annu Rev Pathol. 2017;12:331-357. DOI: 10.1146/annurev-pathol-052016-100401</mixed-citation><mixed-citation xml:lang="en">Schleimer RP. Immunopathogenesis of Chronic Rhinosinusitis and Nasal Polyposis. Annu Rev Pathol. 2017;12:331-357. DOI: 10.1146/annurev-pathol-052016-100401</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Takabayashi T, Schleimer RP. Formation of nasal polyps: Th e roles of innate type 2 infl ammation and deposition of fi brin. J Allergy Clin Immunol. 2020;145(3):740-750. DOI: 10.1016/j.jaci.2020.01.027</mixed-citation><mixed-citation xml:lang="en">Takabayashi T, Schleimer RP. Formation of nasal polyps: Th e roles of innate type 2 infl ammation and deposition of fi brin. J Allergy Clin Immunol. 2020;145(3):740-750. DOI: 10.1016/j.jaci.2020.01.027</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Barrett NA, Shalek AK. Revisiting airway epithelial remodeling in type 2 immunity: Beyond goblet cell metaplasia. J Allergy Clin Immunol. 2019;144(5):1158-1160. DOI: 10.1016/j.jaci.2019.09.017</mixed-citation><mixed-citation xml:lang="en">Barrett NA, Shalek AK. Revisiting airway epithelial remodeling in type 2 immunity: Beyond goblet cell metaplasia. J Allergy Clin Immunol. 2019;144(5):1158-1160. DOI: 10.1016/j.jaci.2019.09.017</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Клиническая иммунология и аллергология: Федеральные клинические рекомендации. Под ред.: Хаитова Р.М., Ильиной Н.И. М.: Фармус Принт Медиа; 2015.</mixed-citation><mixed-citation xml:lang="en">Khaitova R.М., Ilyina N.I., eds. Clinical immunology and allergology: Federal clinical guidelines. Moscow: Farmus Print Media; 2015. (In Russ.)</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Яшина Л.А., Игнатьева В.И. Возможности азеластина в лечении сезонного аллергического ринита в формате нового исследования МР4001. Астма та алергія. 2013;(1):55-58.</mixed-citation><mixed-citation xml:lang="en">Yashina L.A., Ignatieva V.I. Features azelastine in the treatment of seasonal allergic rhinitis in the format of the new MR4001 research. Asthma and allergy. 2013;(1):55-58. (In Russ.)</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">Juniper EF, Th ompson AK, Ferrie PJ, Roberts JN. Validation of the standardized version of the Rhinoconjunctivitis Quality of Life Questionnaire. J Allergy Clin Immunol. 1999;104(2 Pt 1):364-9. DOI: 10.1016/s0091-6749(99)70380-5</mixed-citation><mixed-citation xml:lang="en">Juniper EF, Th ompson AK, Ferrie PJ, Roberts JN. Validation of the standardized version of the Rhinoconjunctivitis Quality of Life Questionnaire. J Allergy Clin Immunol. 1999;104(2 Pt 1):364-9. DOI: 10.1016/s0091-6749(99)70380-5</mixed-citation></citation-alternatives></ref><ref id="cit17"><label>17</label><citation-alternatives><mixed-citation xml:lang="ru">Косаковский А.Л., Гавриленко Ю.В. Аллергический ринит: этиология, патогенез, клинические проявления и патогенетически обоснованная терапия. Укр. мед. журн. 2013;(6):48-51.</mixed-citation><mixed-citation xml:lang="en">Kosakovsky A.L., Gavrilenko Yu.V. Allergic rhinitis: etiology, pathogenesis, clinical manifestations and pathogenetically based therapy. Ukrainian Medical Journal. 2013;6:48-51(In Russ.)</mixed-citation></citation-alternatives></ref><ref id="cit18"><label>18</label><citation-alternatives><mixed-citation xml:lang="ru">Курбачева О.М., Польнер С.А., Смирнов Д.С. Аллергический ринит. Вечная проблема и ее современное решение. Медицинский Совет. 2015;(3):84-91. DOI: 10.21518/2079-701X-2015-3-84-91</mixed-citation><mixed-citation xml:lang="en">Kurbacheva O.M., Polner S.A., Smirnov D.S. Allergic rhinitis. Perpetual problem and current solutions. Meditsinskiy sovet = Medical Council. 2015;(3):84-91. (In Russ.) DOI: 10.21518/2079-701X-2015-3-84-91</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
